Towards individualized dynamic adaptive radiotherapy: Head and Neck Use-Case

Towards Individualized Dynamic Adaptive Radiotherapy: The Head and Neck Use-CasePresented virtually 2026-11-16T0830 Head and neck radiotherapy has advanced through successive paradigm shifts: recognition of HPV-driven disease, the move from 3D-conformal treatment to IMRT and then proton therapy, and now high-frequency on-treatment imaging with the MR-Linac. Each shift reduced dose to normal tissue, yet dose prescription itself remains population-based, resting on the incorrect assumption that all tumors, and all tumor sub-volumes, are equally radiosensitive.This talk argues that spatially resolved, longitudinal dose-response data are radiation oncology’s distinctive asset, and examines what it takes to turn imaging into a decision-grade biomarker. Using the BEST framework and context-of-use statements, it separates technical quantification (QIBA-style metrology) from biological qualification, and proposes that useful quantitative imaging biomarkers must be accurate, anticipatory, actionable, and additive. Diffusion-weighted and IVIM MRI illustrate the promise: early on-treatment ADC change predicts mid-therapy complete response, daily DWI is feasible on the MR-Linac, and functional-imaging-guided sub-volume boosting has been tested prospectively. Dynamic contrast-enhanced MRI illustrates the problem: in an 11-site digital reference object challenge and subsequent in vivo comparison, algorithms disagreed even on whether a patient’s Ktrans fell above or below the median, underscoring the need for acquisition and post-processing standardization before multi-site scaling.The talk closes with Dynamics-Adapted Radiotherapy Dose (DARD), a model that uses early on-treatment tumor volume dynamics to estimate the individual dose needed for local control, cross-validated across CBCT, CT-on-rails, and MR-Linac data. A planned phase II/III randomized trial in HPV-positive oropharyngeal cancer (240 patients, 2:1) will test DARD-personalized dosing of 40–84 Gy against standard 70 Gy, with Q-TWiST superiority as the primary endpoint, gated non-inferiority testing of 3-year progression-free survival, Bayesian futility monitoring, and an HPV ctDNA safety stop. Embedded multiparametric MRI and digital-twin modeling aim to deliver voxel-level recurrence-risk prediction.

Authors

Publication Details

Journal
Figshare
Published
2026-11-16
DOI
https://doi.org/10.6084/m9.figshare.35024992
Primary Topic
Advanced Radiotherapy Techniques
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Towards individualized dynamic adaptive radiotherapy: Head and Neck Use-Case

Clifton David Fuller
Figshare
Advanced Radiotherapy Techniques
article

Towards individualized dynamic adaptive radiotherapy: Head and Neck Use-Case

Clifton David Fuller
article en

Abstract

Towards Individualized Dynamic Adaptive Radiotherapy: The Head and Neck Use-CasePresented virtually 2026-11-16T0830 Head and neck radiotherapy has advanced through successive paradigm shifts: recognition of HPV-driven disease, the move from 3D-conformal treatment to IMRT and then proton therapy, and now high-frequency on-treatment imaging with the MR-Linac. Each shift reduced dose to normal tissue, yet dose prescription itself remains population-based, resting on the incorrect assumption that all tumors, and all tumor sub-volumes, are equally radiosensitive.This talk argues that spatially resolved, longitudinal dose-response data are radiation oncology’s distinctive asset, and examines what it takes to turn imaging into a decision-grade biomarker. Using the BEST framework and context-of-use statements, it separates technical quantification (QIBA-style metrology) from biological qualification, and proposes that useful quantitative imaging biomarkers must be accurate, anticipatory, actionable, and additive. Diffusion-weighted and IVIM MRI illustrate the promise: early on-treatment ADC change predicts mid-therapy complete response, daily DWI is feasible on the MR-Linac, and functional-imaging-guided sub-volume boosting has been tested prospectively. Dynamic contrast-enhanced MRI illustrates the problem: in an 11-site digital reference object challenge and subsequent in vivo comparison, algorithms disagreed even on whether a patient’s Ktrans fell above or below the median, underscoring the need for acquisition and post-processing standardization before multi-site scaling.The talk closes with Dynamics-Adapted Radiotherapy Dose (DARD), a model that uses early on-treatment tumor volume dynamics to estimate the individual dose needed for local control, cross-validated across CBCT, CT-on-rails, and MR-Linac data. A planned phase II/III randomized trial in HPV-positive oropharyngeal cancer (240 patients, 2:1) will test DARD-personalized dosing of 40–84 Gy against standard 70 Gy, with Q-TWiST superiority as the primary endpoint, gated non-inferiority testing of 3-year progression-free survival, Bayesian futility monitoring, and an HPV ctDNA safety stop. Embedded multiparametric MRI and digital-twin modeling aim to deliver voxel-level recurrence-risk prediction.

Figshare
National Institute of Dental and Craniofacial Research
Good health and well-being
Advanced Radiotherapy Techniques
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon